NCT06147986View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 24, 2023

Primary Completion Date

June 24, 2027

Study Completion Date

June 24, 2027

Conditions
ST Elevation Myocardial Infarction
Interventions
BIOLOGICAL

Allogeneic umbilical cord mesenchymal stem cells

UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.

OTHER

Control group

Standard-of-care for STEMI

Trial Locations (1)

Unknown

RECRUITING

China Medical University Hospital, Taichung

All Listed Sponsors
lead

Ever Supreme Bio Technology Co., Ltd.

INDUSTRY